Eculizumab

Eculizumab is a first-in-class terminal complement inhibitor which works by electively inhibiting activation of specific proteins in the complement system (c5 and c5b), which play a role in the treatment of multiple rare diseases.

Nufactor carries the following eculizumab brand:

Brand (Manufacturer)	FDA-Approved Indication(s) [abbreviated]
Soliris^® (Alexion) soliris.net/home/	Generalized myasthenia gravis Neuromyelitis Optica Spectrum Disorder Atypical hemolytic uremic syndrome Paroxysmal nocturnal hemoglobinuria

Last reviewed 01/15/2026